论文部分内容阅读
目的 :探析成人初治急性髓系白血病(AML)治疗中柔红霉素+阿糖胞苷诱导化疗(DA方案)与阿糖胞苷+去甲氧柔红霉素(IA方案)的临床价值。方法 :分析2013年3月~2016年4月在我院接受治疗的72例成人初治AML患者的临床资料。根据诱导化疗方案的不同可以将入选者分成DA组(34例)和IA组(38例)两组。比较两组患者的基线资料、治疗效果、安全性以及生存状况。结果 :两组患者的基线资料无显著差异。IA组1、2个疗程后的总有效率均明显高于DA组。两组患者化疗后均出现感染、恶心呕吐以及骨髓抑制等副反应,且均可耐受。DA组患者的CR复发率(61.3%)比IA组(83.3%)高,差异无统计学意义;中位生存时间(1.8年)比DA组(1.2年)长。结论 :与DA方案相比,IA方案治疗初治成人AML的疗效更为突出,临床上值得进一步推广和应用。
Objective: To investigate the clinical value of daunomycin + cytarabine induction chemotherapy (DA regimen) and cytarabine + daunorubicin (IA regimen) in adult patients with acute myeloid leukemia (AML) . Methods: The clinical data of 72 adult patients with newly diagnosed AML treated in our hospital from March 2013 to April 2016 were analyzed. According to different chemotherapy regimens, participants were divided into DA group (34 cases) and IA group (38 cases). Baseline data, treatment outcomes, safety, and survival status were compared between the two groups. Results: There was no significant difference in baseline data between the two groups. The total effective rate of IA group after 1 and 2 courses of treatment was significantly higher than that of DA group. Two groups of patients after chemotherapy were infected, nausea and vomiting and bone marrow suppression and other side effects, and can be tolerated. The CR recurrence rate in DA group (61.3%) was higher than that in IA group (83.3%), with no significant difference. The median survival time (1.8 years) was longer than that in DA group (1.2 years). Conclusion: Compared with the DA regimen, the efficacy of IA regimen in the treatment of newly diagnosed adult AML is more prominent and worth further promotion and application in clinic.